Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029796 · ClinicalTrials.gov registry record · Phase 2
Isoflavones and Acute-phase Response in Chronic Renal Failure
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00029796 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 52 participants.
The verdict
NCT00029796, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a randomized, double-blinded dietary intervention in hemodialysis patients to determine the clinical and metabolic effects of soy isoflavones on disease activity, including improvement of blood markers of acute-phase response, and decreased blood levels of markers of metabolic bone disease.
Interventions
- DRUG soy isoflavones
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029796
The ClinicalTrials.gov registry entry for NCT00029796 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which soy isoflavones is the first listed.
NCT00029796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029796 about?
NCT00029796 is a clinical study titled "Isoflavones and Acute-phase Response in Chronic Renal Failure". This is a randomized, double-blinded dietary intervention in hemodialysis patients to determine the clinical and metabolic effects of soy isoflavones on disease activity, including improvement of blood markers of acute-phase response, and decreased blood levels of markers of metabolic bone disease.
What is the current status of trial NCT00029796?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00029796?
The interventions under investigation include: soy isoflavones (DRUG).
Who is sponsoring clinical trial NCT00029796?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.